Study shows thalidomide of little benefit in small cell lung cancer
스크롤 이동 상태바
Study shows thalidomide of little benefit in small cell lung cancer
기자명
메디칼라이터팀
입력 2009.07.20 00:00
수정 2009.07.21 00:02
댓글 0
In a study of 724 patients who received 100 to 200 milligrams a day of thalidomide or the placebo for up to two years, the median overall survival for patients in the thalidomide group was 10.1 months, compared to 10.5 months for those in the placebo group. Those on the drug increased their risk of blood clots. According to researchers, there is a need to take a new look at the basic biology of small cell lung cancer. Thalidomide, used as a treatment for morning sickness, was banned after it led to birth defects.